Sage Therapeutics 因中期试验无效而停止阿尔茨海默病药物开发。 Sage Therapeutics halts Alzheimer's drug development due to mid-stage trial inefficacy.

Sage Therapeutics已停止其阿尔茨海默病药物dalzanemdor的开发，此前与安慰剂相比，中期试验未能显示出治疗轻度认知障碍和轻度痴呆的显着疗效。 Sage Therapeutics has halted development of its Alzheimer's drug, dalzanemdor, after a mid-stage trial failed to show significant efficacy compared to a placebo in treating mild cognitive impairment and mild dementia. 这一挫折是继停用另一种药物Zurzuvae(Zurzuvae)治疗临床抑郁后出现的。 This setback follows the discontinuation of another drug, zurzuvae, for clinical depression. 尽管存在这些挑战,Sage计划继续对亨廷顿疾病进行达尔扎内姆多的检测,预计今年晚些时候将取得结果。 Despite these challenges, Sage plans to continue testing dalzanemdor for Huntington's disease, with results expected later this year. 宣布后,公司股票下跌了12%左右。 The company's shares dropped about 12% following the announcement.